Last reviewed · How we verify
Treatment with Apremilast
Apremilast, marketed by the University of South Florida, is a therapeutic agent currently on the market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not provided. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Treatment with Apremilast |
|---|---|
| Also known as | Otezla |
| Sponsor | University of South Florida |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Apremilast and Adalimumab in Psoriatic Arthritis Patients (NA)
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PHASE3)
- Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece
- Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder (PHASE2)
- A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO) (PHASE3)
- A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment with Apremilast CI brief — competitive landscape report
- Treatment with Apremilast updates RSS · CI watch RSS
- University of South Florida portfolio CI